ISSWSH ISSUES IMPORTANT UPDATES FOR HSDD THERAPIES

ISSWSH is pleased to provide the following updates related to therapies for Hypoactive Sexual Desire Disorder or HSDD. The FDA has updated prescribing information for flibanserin, removed the REMS certification requirement for prescribers and pharmacists, and updated safety information related to the alcohol contraindication. In addition, bremelanotide has now been approved for treatment of HSDD. Please see the attached news release related to these two therapies for more specific information and references.

News Release

Save the Date

ISSWSH Fall Course 2020
Cancelled

ISSWSH Virtual Course 2020
November 6, 13, & 20, 2020  
Virtual
Stay tuned for updates

ISSWSH Annual Meeting 2021
March 4-7, 2021   210 days left
Renaissance Dallas Hotel, Dallas, TX, USA

Latest Tweets

Well if this isn't another good reason to have sex - delay menopause. https://t.co/cgeHZMfyzo ISSWSH
It's good to be alive now! 250 years ago, over one-fifth of Londoners had contracted syphilis by their 35th birthda… https://t.co/k0gRN0ZR0B ISSWSH
Wondering how to get your grove on? How to initiate sex https://t.co/X41FW5AlPS ISSWSH

Contact Details

ISSWSH Executive Office
14305 Southcross Dr
Suite 100
Burnsville, MN 55306
USA

Phone: +1 (952) 683 9025
Fax: +1 (952) 314 8212
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow Us

On Twitter
On Facebook
On Instagram